Akses terbuka
Jurnal
SINTA 1
Predictors of persistent high disease activity after methotrexate treatment in rheumatoid arthritis patients
Universa Medicina · Vol. 44 No. 2 (2025) · hlm. 141–151
ISSN 2407-2230, 1907-3062
Terbit 2025-07-04
Penerbit Faculty of Medicine, Universitas Trisakti
Bahasa eng
Abstrak
Background Methotrexate (MTX) is the firstline therapy for rheumatoid arthritis (RA). However, 30–40% of RA patients exhibit poor response. Identifying early factors associated with persistent disease activity is critical to guide treatment. This study aimed to identify predictors of persistent high disease activity (DAS28-ESR >3.2) after six months of MTX therapy in RA patients. Methods A retrospective cohort study was conducted involving 204 RA patients who had completed six months of MTX therapy. The primary outcome was DAS28-ESR score at six months. Independent variables included baseline erythrocyte sedimentation rate (ESR), cumulative doses of MTX and low-dose methylprednisolone (LDM), and rheumatoid factor (RF) status. Simple and multiple logistic regression was used to analyze the data. Results Significant differences in ESR and cumulative MTX dose were observed between low and high disease activity groups. Multivariate analysis identified four independent predictors of persistent high disease activity (DAS28-ESR >3.2) after six months of MTX therapy: disease duration >11 months (AOR =0.45; 95% CI 0.23–0.89; p=0.025); age at onset >50 years (AOR 0.48; 95% CI 0.24–0.94; p=0.038); cumulative MTX dose >85 mg (AOR 4.75; 95% CI 1.55–14.64; p=0.006); ESR >66 mm/hr (AOR 2.32; 95% CI 1.11–4.89; p=0.026). Conclusion Greater cumulative methotrexate dose (>85 mg) was the most influential predictor of persistent high disease activity (DAS28-ESR >3.2) after six months of MTX therapy in RA patients. These findings may assist clinicians in identifying patients at risk for poor MTX response and support timely therapeutic adjustments.
Jaringan kolaborasi para penulis
11 penulis ·
22 tautan kepenulisan bersama
· 11 lintas organisasi
Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.
Universitas Gadjah Mada Rumah Sakit Umum Pusat Dr. Sardjito Afiliasi tidak diketahui
Organisasi berbeda
Organisasi sama
Afiliasi tidak diketahui
Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.
Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title xml:lang="en">Predictors of persistent high disease activity after methotrexate treatment in rheumatoid arthritis patients</dc:title>
<dc:creator xml:lang="en">Paramaiswari, Ayu </dc:creator>
<dc:creator xml:lang="en">Kertia, Nyoman </dc:creator>
<dc:creator xml:lang="en">Achadiono, Deddy </dc:creator>
<dc:creator xml:lang="en">Sinarta, Armin </dc:creator>
<dc:creator xml:lang="en">Nugroho, Dhite</dc:creator>
<dc:subject xml:lang="en">Persistent disease activity</dc:subject>
<dc:subject xml:lang="en">rheumatoid arthritis</dc:subject>
<dc:subject xml:lang="en">methotrexate</dc:subject>
<dc:subject xml:lang="en">DAS28-ESR</dc:subject>
<dc:subject xml:lang="en">predictors</dc:subject>
<dc:description xml:lang="en">Background
Methotrexate (MTX) is the firstline therapy for rheumatoid arthritis (RA). However, 30–40% of RA patients exhibit poor response. Identifying early factors associated with persistent disease activity is critical to guide treatment. This study aimed to identify predictors of persistent high disease activity (DAS28-ESR &gt;3.2) after six months of MTX therapy in RA patients.
Methods
A retrospective cohort study was conducted involving 204 RA patients who had completed six months of MTX therapy. The primary outcome was DAS28-ESR score at six months. Independent variables included baseline erythrocyte sedimentation rate (ESR), cumulative doses of MTX and low-dose methylprednisolone (LDM), and rheumatoid factor (RF) status. Simple and multiple logistic regression was used to analyze the data.
Results
Significant differences in ESR and cumulative MTX dose were observed between low and high disease activity groups. Multivariate analysis identified four independent predictors of persistent high disease activity (DAS28-ESR &gt;3.2) after six months of MTX therapy: disease duration &gt;11 months (AOR =0.45; 95% CI 0.23–0.89; p=0.025); age at onset &gt;50 years (AOR 0.48; 95% CI 0.24–0.94; p=0.038); cumulative MTX dose &gt;85 mg (AOR 4.75; 95% CI 1.55–14.64; p=0.006); ESR &gt;66 mm/hr (AOR 2.32; 95% CI 1.11–4.89; p=0.026).
Conclusion
Greater cumulative methotrexate dose (&gt;85 mg) was the most influential predictor of persistent high disease activity (DAS28-ESR &gt;3.2) after six months of MTX therapy in RA patients. These findings may assist clinicians in identifying patients at risk for poor MTX response and support timely therapeutic adjustments.</dc:description>
<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
<dc:date>2025-07-04</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/1754</dc:identifier>
<dc:identifier>10.18051/UnivMed.2025.v44.141-151</dc:identifier>
<dc:source xml:lang="en">Universa Medicina; Vol. 44 No. 2 (2025); 141-151</dc:source>
<dc:source>2407-2230</dc:source>
<dc:source>1907-3062</dc:source>
<dc:source>10.18051/UnivMed.2025.v44.i2</dc:source>
<dc:language>eng</dc:language>
<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/1754/825</dc:relation>
<dc:rights xml:lang="en">Copyright (c) 2025 Ayu Paramaiswari, Nyoman Kertia, Deddy Achadiono, Armin Sinarta, Dhite Nugroho</dc:rights>
<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>
Sitasi dan pengindeksan
Jumlah menurut tiap indeks pada 13 Nov 2026; setiap indeks menghitung sitasi dengan cara berbeda.
OpenAlex juga mencatat karya ini di: crossref, doaj.
Sitasi artikel ini
APA 7
Paramaiswari, A., Kertia, N., Achadiono, D., Sinarta, A., & Nugroho, D. (2025). Predictors of persistent high disease activity after methotrexate treatment in rheumatoid arthritis patients. Universa Medicina, 44(2), 141–151. https://doi.org/10.18051/UnivMed.2025.v44.141-151
Salin
IEEE
A. Paramaiswari, N. Kertia, D. Achadiono, A. Sinarta, and D. Nugroho, “Predictors of persistent high disease activity after methotrexate treatment in rheumatoid arthritis patients,” Universa Medicina, vol. 44, no. 2, pp. 141–151, 2025, doi: 10.18051/UnivMed.2025.v44.141-151.
Salin
Dibuat dari metadata jurnal; periksa nama penulis sebelum dipakai.